Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Annovis Bio, Inc. (ANVS)

Annovis Bio receives NYSE continued listing notice over market cap and equity

Negative Impact 4 of 5 legal/regulatory Written later

Annovis Bio received a New York Stock Exchange notice on October 29, 2026, that it no longer meets continued listing standards because its 30-day average market capitalization and stockholders' equity were both below $50 million. The company has 9 months to regain compliance, and its common stock will keep trading under the symbol ANVS with a ".BC" designation while it works on a plan.

Key points

  • NYSE notice received October 29, 2026, under Section 802.01B of its Listed Company Manual
  • 30-day average market capitalization was approximately $48.4 million as of October 28, 2026
  • Stockholders' deficit was approximately $(4.3) million as of June 30, 2026
  • Company must submit a compliance plan within 45 days of the notice; cure period is 9 months

The filing

CompanyAnnovis Bio, Inc. (ANVS)
Form8-K, current report
Filed with the SECOct 30, 2026, 5:10 PM ET
Accession number0001104659-26-120732

Items reported: 3.01 Delisting / Listing Rule Notice7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.